Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study - PubMed
6 hours ago
- #immunotherapy
- #real-world outcomes
- #non-small cell lung cancer
- The I-STOP study evaluated outcomes of discontinuing or continuing immune checkpoint inhibitors (ICIs) after 24 months in advanced non-small cell lung cancer (NSCLC) patients with disease control.
- Among 173 patients, 16.2% discontinued ICIs at 24 months. No significant difference in overall survival (OS) was found between discontinuation and continuation groups.
- Progression-free survival (PFS) was shorter in the discontinuation group (35.6 months vs. not reached in continuation group).
- Higher progression risk post-discontinuation was noted in patients with PD-L1 ≤ 50%, brain metastases, ECOG PS ≥ 1, or KRAS mutations.
- Rechallenge with ICIs achieved a 62.5% response rate, and late grade 3-4 immune-related events were rare (3.5%).
- Discontinuing ICIs at 24 months appears safe for patients with durable disease control, though some subgroups may benefit from continued treatment.